500 tables processed...
1000 tables processed...
1500 tables processed...
2000 tables processed...
2500 tables processed...
3000 tables processed...
3500 tables processed...
4000 tables processed...
4500 tables processed...
5000 tables processed...
5500 tables processed...
6000 tables processed...
6500 tables processed...
7000 tables processed...
7500 tables processed...
8000 tables processed...
8500 tables processed...
9000 tables processed...
9500 tables processed...
10000 tables processed...
10500 tables processed...
11000 tables processed...
11500 tables processed...
12000 tables processed...
12500 tables processed...
13000 tables processed...
13500 tables processed...
14000 tables processed...
14500 tables processed...
15000 tables processed...
5 iterations done
10 iterations done
15 iterations done
20 iterations done
25 iterations done
30 iterations done
35 iterations done
40 iterations done
45 iterations done
50 iterations done
55 iterations done
60 iterations done
65 iterations done
70 iterations done
75 iterations done
80 iterations done
85 iterations done
90 iterations done
95 iterations done
100 iterations done
Type 0 (2959): 37.4| 37.5| 37.7| 11.5| 11.4| 11.3| 11.2| 11.1| 11.8| 11.6| 
Type 1 (905): ?41.49±0.78| ?41.14±0.61| 25.19(0.24)| 19.59±3.06*| 3.19×10?11| 2.25?10-15| 6.65×10?11| 0.157(139)| 4.25×10?15| 2.51×10-11| 
Type 2 (189): Regulation of transcription| No histologic abnormalities| Synthesis of prostaglandins| Strategy for identification| Other clonal abnormalities| Cell cycle; Cell proliferation.| Prostaglandin E biosynthesis| 8 Peritoneal carcinomatosis| Regulation of MT stabilization| Temsorolimus + tranbectedin| 
Type 3 (96): 5'-GCTTTCTGCCATTCTCATCG-3'| 5?-CTTGGCATACATCAGGTCAA-3?| 5'-TTTCAGGAGCTCGGTACCAC-3'| 5?-GGACTTCGAGCAAGAGATGG–3?| 5?-AGCACTGTGTTGGCGTACAG-3?| 5'-GGTTACCAGGGCTGCCTTCT-3'| 5?-TGCTTTCCATCGGCCYAAAA-3?| 5?-CACCCACTCCTCCACCTTTG-3?| 5?-CACCGTCAAGCAGCGTGTAC-3?| 5?-GGGATTAGAATTTTTTTATG-3?| 
Type 4 (540): Network building| Astacin protease| Grifola frondosa| Pleural effusion| Epstein syndrome| Choline chloride| Shimada category| Spindle assembly| Gelatin hydrogel| Frontal regionsb| 
Type 5 (36): DVL3; LATS1; FZD4; TP73; TCF7L2| (iii) PRKCB* : HIST1H3I : CUL4A : CUL1| ATG5; ATG7; ATG12; MAP1LC3B; BECN1| CAMA-1 (R280T)MDA-MB-231 (R280K)| VEGFR-1, VEGFR-2, and VEGFR-3| IL-1R IL-6R (CD 126) CXCR-1 CXCR-2 IL-11R| PPAR-?, p53, CHOP-10, CREB, CRE-BP2| RA/RARS (37) RAEB/RAEB-t (51) CMML (11)| P2 (MEK1 siRNA-7811 + MEK2 siRNA-914)| 21 LILSCICL 8 LILSCICL ********| 
Type 6 (288): Naito et al. ( 2014 )| Costa et al. ( 2011 )| Leigh et al. ( 2013 )| Zhang et al. ( 2012 )| Sivan et al. ( 2013 )| Campos et al. ( 2012 )| Lakner et al. ( 2012 )| ( Craig et al., 2012 )| ( Atefi et al. , 2011 )| Tsuji et al. [ 114 ]| 
Type 7 (5): cgaagcttttatcttagtcttttatatttctttaataaag| atgactgaatataaacttgtggtagttggagctggtgXcgta| https://basespace.illumina.com/home/index| ggttaattttagttagttatttattgggagtttt| 5’-ctataaaaggggtgatataacgctctccaag-3’| 
Type 8 (266): SOD2/GAPDH| ABCG2/BCRP| GYPGQV-NH2| USO1_HUMAN| IL3B_HUMAN| PTEN/MMAC1| pGEX-RACK1| KIF5B->RET| MHH-TALL-1| EGFR/HER-1| 
Type 9 (3): CGAGCTCAAGCTTCGAATTCTGATGTTTCGTAAAGCAACCAGG| CCTGGTTGCTTTACGAAACATCAGAATTCGAAGCTTGAGCTCG| AAAAGCAAATAAGGCTAGACAAAGTTCGCTTTGTCTAGCCTTATTCTGC| 
Type 10 (189): Delivers exocytic vesicles to plasma membrane| Transcription factor Tubby signaling pathways| Deletion strain collection research genetics| Protein folding_Response to unfolded proteins| Percentage of contigs functionally annotated| Details about receptor expression not provided| Demehtylation of Histone or non-histone proteins| Zinc-finger nuclease to target steroid receptor| Housekeeping gene used as internal reference| Growth inhibition and induction of apoptosis| 
Type 11 (188): IL-22 induces senescence in HSCs| Allosteric inhibitor of LOX-L2| Glial cells (expressing GFAP)| Santa Cruz Biotechnology (CA)| Gastric carcinoma SNU-5 cells| Differential response to CT/RT| MiR microarray profiling; qPCR| RAB10, member RAS oncogene family| GATA3 (dichotomous, low vs. high)| Add during perfusion with EGTA| 
Type 12 (94): Immunoglobulin-like| Radiation-resistant| Medroxyprogesterone| Multiphosphorylated| Ubiquitin-proteasome| advanced/pretreated| relapsed/refractory| Tetrathiomolybdate| Isopentenyladenine| Cholangiocarcinoma| 
Type 13 (258): PI3K & HDAC| CDH13 / RIL| STAT1???GBP1| CDDP + GEM| STIL / SIL| PTEN + FAK| LET + BEV| AOM + DSS| PAF + CFW| CPT + CTX| 
Type 14 (1068): Ferritin| Afatinib| Allergen| Melanoma| Diabetes| deepBase| Matching| Antibody| Squamous| Apigenin| 
Type 15 (161): Epidermal growth factor receptor (EGFR)| Homodimer or heterodimer with C/EBP?/?| Development: EGFR signaling pathway| Over-expressed in BPH and PCa vs benign| IFN?-treated murine BV-2 microglia cells| collagen II; MOG petide; islet lysate| BRCA1 associated ring domain protein| Detect the presence of BAP-1 mutation| Ozone-induced neutrophilia COPD Asthma| Containing an open reading frame (ORF)| 
Type 16 (15): IL28B [ 230 , 232 , 233 , 238 , 289 ]| [ 47 , 49 , 147 , 178 , 213 – 219 ]| [ 231 , 249 , 250 , 251 , 252 , 253 , 261 ]| [ 142 , 148 , 149 , 155 , 156 ]| [ 102 , 167 , 172 , 280 – 282 , 296 – 298 ]| [ 257 , 255 , 256 , 259 - 258 ]| [ 245 , 251 , 252 , 253 , 254 , 255 , 256 ]| 33 , 164 , 165 166 31 167 67 209 210| FGF-1, 2, 4, 6, 8, 9, 16, 17, 18, and 19| 3, 5, 7, 8, 17, 19, 24*, 32, 34, 35, 36, 37| 
Type 17 (8): www.clinicaltrials.gov/NCT00617890| rno-mir-181a-2//mir-181a-1(MSub)| 20,22-epoxyeupha-24-ene-3-one| age-1(lf);daf-18(lf);let-60(gf)| 1–18:2-Lysophosphatidylglycerol| IPR017441:Protein_kinase_ATP_BS| polyhomeotic_like protein 1 - PHC1_HUMAN| http://mint.bio.uniroma2.it/mint/| 
Type 18 (351): 293.11 ± 90.44| 50.739 ± 2.145| 236.11 ± 29.05| 173.05?±?16.47| 242.86 ± 70.15| 2.282 ± 0.617| 16.43?±?10.58| 55.58 ± 10.12| 2.917 ± 0.818| 52.32 ± 10.11| 
Type 19 (5): GR212046GR212052GR212105GR212131| AJ927925AJ927897AJ927925AJ927925| NT_034772.6(22829799-22829407)| FOSL2.PLB1..chr2.28628327.28860856_AMP| 14967450,16680569,11349215,11344033| 
Type 20 (92): 3? UACGGG AAAAU UGU AACGUGA C| GTT CGC GTG GCG TAA GAG TAC| GCA TAA TGG GAA ACC GTG TAG| TTG CTC AGA ACT TAT ACC ACG| CAA TAG TGA TGA CCT GGC CGT| CTT CTT GCA CAC CAT CTC GTT| GTT TGG GGC ACA ACA CGT CAG| FP: 5' GCAGATCGACCCCAATTTTG 3'| TGC TTC ACC ACC TTC TTG AT| GTA ACC CGT TGA ACC CCA TT| 
Type 21 (530): Normal tissue| Gallus gallus| Carica papaya| Normal marrow| Breast cancer| Animal models| Gingko biloba| Buccal mucosa| Paired domain| Glomus tumour| 
Type 22 (266): Cathepsin B preproprotein-like protein| Accessory calcium channel beta-2 subunit| Natural Killer cell activating receptor| Follicular fluid Granulosa cells Oocyte| Impaired T-dependent antibody response| Infarction and creatine kinase release| Zinc finger X-linked Duplicated protein| One-carbon compound metabolic process| Maxillary diastema Mutants with 4 molars| Colorectal cancer and Prognostic factors| 
Type 23 (127): Wild K-RAS (n = 48)| Late DOWN (n = 29)| GC for PAR-2 [ 57 ]|  LI?<?32% vs. LI???32%| NSAIDs ( n ?=?22)| High CD63 (n?=?81)| 5-day SLP ( n ?=?8)| 3-year DFS 65% OS 83%| FINHer ( N = 232)| 15% vs. 8% DeTC 36% MTC| 
Type 24 (332): High cholesterol gr 3–4| Complete remission 17%| Pressure cooker, 2?min| Germline tumors at 25°C| Sartore-Bianchi et al.| ribosomal protein L26| ribosomal protein L22| Ring finger protein 160| Kruppel-like factor 10| Ran-binding protein 10| 
Type 25 (26): hsa-miR-20aSTAR-4395548| hsa-miR-409-3p-4395443| hsa-miR-30aSTAR-4373062| hsa-miR-374aSTAR-4395236| hsa-miR-337-5p-4395267| hsa-miR-768-3p-4395188| scaffold_56:13693-16737| GgaAffx.3294.1.S1_at| gene11999-v1.0-hybrid| AC204864.2-Contig55| 
Type 26 (15): F:TTAAATGGTGCAACTCTG R:TGGATGGTACTAAGAAGAAC| GGGTGGGAGGTGGGAGGG ATCCCCACTCTCCTATCTAAT| F: CTGTTCGCGCTCTCGGCAG R: CCAGTAGCCACAGCAGCGG| F: TACCAGATCGCGCCCATCTA R: GATGGCCTCGATGCGCTTC| F: ACCAGATGCCCTACACTACC R: GTGCATAAATGGAGAGTGTG| F: CAACGTCATCTACCGTGACC R: AAATACTCCGGTGTCCCACA| F: ACCACAGTCCATGCCATCAC R: TCCACCACCCTGTTGCTGTA| TACATCACTGGTAAGAGCAAAGA TACACCACCTCAAAGCCCCG| CGCGGTGGCTGTCATCA AGGGTTGGGTCCCAGGAAT| KEGG_COMPLEMENT_AND_ COAGULATION_CASCADES| 
Type 27 (1137): Fabp5| Abcf2| Ireb2| Htr2b| Oasl2| Irgm1| Akap6| Sirt7| Tgfb1| Dauv1| 
Type 28 (10): 5?-CGCACAAGCTTCAAT AATGGAGCTGAGGAG-3?| DIAPHANOUS HOMOLOG 1 (DROSOPHILA)| MASCOT;UNIPROT KB/SWISS-PROT;COGS| SIG_PIP3_SIGNALING_IN_B_ LYMPHOCYTES| VFLENVIR(34) AVTYTEHAK(33) ISGLIYEETR(40)| GGTGCAGCATTT AGT ACACCCAGAGCC| CTCCTGCGGGCGTCT TCCTTGGCAAC| 5?-CCGCGCACTAGTTCAA AATGTATTAGAGATCCC-3?| L1CAM INTERACTIONS (REACTOME)| CCCCCTGCCCCTCCC ATATTCTCCC| 
Type 29 (178): siRNA for RSV (viral gene)| Two-component GAP Byr4| Arp2/3 complex; actin; VASP| Histology (AO versus AOA)| The virus itself (PAMP)| Etoposide ? c-PARP | Total| UNG activation 2 min, 50°C| Placental Weight (SDS)| alcA::pkcA ?cnaA , cho1| Upregulation of FOXD3| 
Type 30 (26): chr9:99086401–99122485| 145268084-149114686| chr9:21967751-21994490| X:53224324:53225545| chr7: 73605528-73605624| chr6:31695894-31698245| 45758758–45770619| 22890122-25024973| 59257566/56499445| Chr. 8: 11,728,105–11,835,219| 
Type 31 (819): 1.03±0.08| 1.03±0.10| 0.34±0.09| 0.09–0.44| 0.45±0.05| 0.45±0.03| 0.45±0.10| 0.04–0.22| 0.86±0.06| 10.60±0.7| 
Type 32 (439): In atropic endometrium| Cortex and hippocampus| Cell cycle progression| Inducible conditional| Diffusion coefficient| Structure undisclosed| Cetuximab monotherapy| Neisseria gonorrhoeae| Signal of degradation| Nutrient deprivation| 
Type 33 (987): OVE26-L| Q61L/WT| CH2-CH2| TOAD-64| SENP5-7| SUP-B15| GLUT-12| 5PP-IP5| LFM-A13| 4E-ASO4| 
Type 34 (1266): 10 (77%)| 40 (2/5)| 10 (31%)| 50 (77%)| 60 (17%)| 20 (43%)| 17 (30%)| 57 (50%)| 54 (50%)| 13 (30%)| 
Type 35 (1): 5?-FAM-(TA)2GC(TA)2AGAT6TCT(TA)2GC(TA)2-TAMRA-3?| 
Type 36 (73): 76 months (95% CI 55–97 months)| Arm 1: 1.7 mg/m2 Arm 2: 1,6 mg/m2| ?-Actin (121, 122) ruvB-like 2 (89)| miR-192 miR-29c miR-26b miR-200b| Ser339 (2 H bonds), Val335| sd::Gal4/+; corto 07128b /rho EP3704| miR-42, miR-70, miR-77, miR-229, miR-273| miR-16, miR-34c, and miR-199a| T820fs*7 and P1439fd*34 ( n =1)| Uehara-Y et al. Nature 373: 702 (1995)| 
Type 37 (55): Pentose and glucuronate interconversions| Involvement in adipocyte differentiation| Contact and delayed type hypersensitivity| Native albumin and probably modified-albumin| Alphav integrin inhibitor, antiangiogenesis| Neurotoxicity, fatigue and thrombocytopenia| Transfection with anti-miR-92b oligonucleotide| Abdominal pain, fatigue and thrombocytopenia| Hydrocephalus, 50% mortality, Hyperinsulinemia| Ipilimumab after adjuvant chemoradiation| 
Type 38 (33): BST2, DGKG, GAS1, PDCD4, TGFBR3, VEZF1| CETS168, CMYB, IK1, MYCMAX, NRF2, TFIII| INADL, NRK, ODZ2, PPAP2C, RAB21, RLIM| CHEK1, CDC2, SERPINE1, STEAP3, CCNE2| F11, LGALS3, CTGF, PGLYRP1, LGALS9, FN1| HSPB6, SLIT2, CPXM2, EFEMP1, CHODL| CDKN2A/B , ETV6 , IKZF1 , CREBBP , NT5C2| SGMS1, PTEN, ALOX12, PRKAG3, PLCD4| APAF1, EP300, EDNRA, CFL2, NOS1, SOX4, SOX11| ADAMTS8, MMEL1, TIMP3 , TLL1, USP46| 
Type 39 (70): 165.1 (103.4, 289.2)| 36,476,724 (81.93%)| 418/2,335 = 17.90%| 12,368,292 (7.96%)| 171, 172, 174-176| 30361298 - 30787250| 8.6 (95% CI: 1.909 - 15.291)| 93 (32.2)/196 (67.8)| 0.557 (0.197 - 1.575)| 8.4 (95% CI: 2.163 - 14.637)| 
Type 40 (200): XM_003640893.1| NM_001025242.1| XM_002711016.1| NM_001128204.1| NM_001031733.1| XM_001714660.1| ?5.03/1.59E-06| Mm00446973_m1*| 4.32±0.84×10?6| XP_002577487.1| 
Type 41 (133): Msx1d/dMsx2d/d| hsa-miR-675_st| hsa-miR-34a-3p| hsa-miR-762_st| Sydh_Ntd1_Znf274| hsa-miR-548c-3p| hsa-miR-199a-3p| mmu-miR-125b-5p| hsa-miR-125b-5p| hsa-miR-181a-3p| 
Type 42 (98): Humans: 150?mg?IM every 3 months [ 122 ].| No risk factors (>50% of all PTBs) 29| Leung-Hagesteijn et al. 2013 [ 77 ]| CoQ10 (5 mM) and simvastatin (240 µM)| 15 (12.3%) More common in exon 20 Lower RR| Microcephaly ( Sir et al., 2011 )| Fabbri et al. (2007a ), Mott et al. (2007 )| ?Average cell length > 129? ? m, (%)| Chawla (in press), Chawla 2011 88 , 89| Survival rate at 2 years (95% CI)| 
Type 43 (388): % inhibition 5 µM| Frank-Raue et al 55| forkhead box M1| Kitahara et al . 41| Breast cancer 90| Super active p53| Seligson et al. 60| Pecorelli et al 97| Vermorken et al 78| Massimino et al 35| 
Type 44 (27): [Swiss Prot:ANXA2_HUMAN]| Grx1/GSH/SAM/Selenite| [Swiss Prot:HNRPD_HUMAN]| MAT? ras1::ade2+pG7RAS1-NAT| TrxR/Trx/SAM/Selenite| RT-PCRMassARRAYTaqMan| DAC+TSA+Paclitaxel| shRB-HRasV12-HA-hMDMX| uPA-Nox1/Nox4; PDGF-Nox1-cofilin| MZ (IgD?IgMhiCD21hi)| 
Type 45 (27): V4 = 2.3 × 106 K4 = 3 × 104 kint = 0.19| c1?=?69; c3?=?14; c4?=?50; c5?=?0.78| F (1, 27) = 0.019; P level = 0.892| F (1, 9) = 0.463; P level = 0.513| 62% ( n = 41) ?24.2% ( n = 16)| 95°C 30?s; 59°C 30?s; 72°C 30?s| 10.7% ( n = 7) ?3.1% ( n = 2)| F (1, 7) = 0.011; P level = 0.920| AL: [ 119 - 122 ] ?C: [ 120 - 122 ]| yes 72.7% ( n = 48) ?no 27.3% ( n =18)| 
Type 46 (129): OVA + siRNA SOCS3| FHIT, WWOX or FUS1| ARHGEF10 (Rho GEF)| RASSF1A , PRSS3| ?CT TGF-?1 mRNA| ZN-FINGER, C2H2| IL8, POTEH, IGF2| MIF, PRAME, GGT1| CHIP (HEG vs. LEG)| VEGFR2; RET and MET| 
Type 47 (328): A549-Snail| miR-30a-5p| Tal-1?/E47| Ma-Mel-123| mGluR4/6/7| miR-590-3p| miR-490-3p| miR-487a?| miR-17-5p| Smad1/5/8| 
Type 48 (389): Similar to Sec-type pathways| Abdominal pain and diarrhea| Number of germline chimeras| Reduction in blood pressure| Median duration of response| Inhibition of cell invasion| mDC from asthmatic patients| Diffuse large B-cell lymphoma| G-protein coupled receptor| Regular physical activity| 
Type 49 (67): CTCAACTACATGGTCTACATGTTCCA| AGAGGATCCATGCAAATGGACGTACG| R-CCATACAGTCTTATCTGATCATGC| CAACACCCTGGCCGAGTTGGTTCAT| TCAGTGCCTTCGGACTGTCTATTTG| CCGGAGUGGCAUCUCAACUCGGAUU| AAAAAACCAATACCCTATCTCTACC| ATACTCACAAAACCCCAAACTAAAC| CCTGAGAGAAACTAACCTGGAGTCA| GTCCTTATGCTCTTTCTTCCACTTC| 
Type 50 (267): Small proline-rich protein 2A| ?Insulin-like growth factor 1| Fatty acid-binding protein 1| Keratin, type I cytoskeletal 19| AT-rich interactive domain 3B| Collectin sub-family member 10| Percentage exome covered at 20×| Hepatocellular carcinoma [ 28 ]| myocyte enhancer factor 2C| Apale and B spermatogonia (n)| 
Type 51 (11): RIKEN cDNA 5330437I02 gene (Mm.183576, NM_177028)| BTT02607_1, BTT4508_1, BTT20259_1, BTT40693_1| MTHFRC677T , MTRR (rs1801394, rs162049, rs10380)| BMS-936559, MSB0010718C, MPDL3280A| C634R; C634W; C634Y; E632_L633del; M918T; A664D| [ 307 ] NCT01632306 NCT01287520 NCT01214603| C634R, C634W, C634Y, E632_L633del, M918T, A664D| ANKFY1, FHL2, KIAA0133, LOC144097, C14orf150| CD63 FLJ20559 GP2 AB065858| PD168368; PD176252; A-716223| 
Type 52 (552): BMS-204352| EHI_164430| PKF118–310| RP11-107B3| BMS-690514| GO:0043565| GO:0031684| GO:0016892| GO:0051186| GO:0051329| 
Type 53 (135): Hugl2 shRNA (MH2C)| 30 (SRS after WBRT)| IDC stage I–III| SphK1 siRNA -AuNP| Phase II (HRPC)| ?IGFBP-3 IHC score| NOD/SCID mouse| ID8 (EOC, mouse)| ECM/MEM genes| GBM_TGF Cancer| 
Type 54 (66): 131I-TM601 (scorpion venom peptide), CC-8490| Ixodes scapularis : XP_002411967 (tick)| MM-121 (SAR256212) + irinotecan + cetuximab| 16q24: MC1R (melanocortin receptor)| RO-4929097 + Paclitaxel + Carboplatin| lte1-8N-3HA ; under GAL1-10 promoter control| Vacuolar protein sorting 35 (VPS35)| HCT116 cells p53+/+ without DNA damage| Tumor protein D52-like 2(Tpd52l2)| Slice culture (CA1 region at DIV9–11)| 
Type 55 (1): TRGC2///TRGV9///LOC442532///LOC442670///TARP| 
Type 56 (443): Increased drug efflux| No significant lesion| Advanced solid tumors| Sponge plasmid vector| Tumor necrosis factor| Yeast suicide protein| Total patient numbers| Toxic thyroid adenoma| Pooled normal tissues| Diabetes with aspirin| 
Type 57 (313): Phosphorylated| Downregulation| Geranylgeranyl| Hyperkeratosis| Ubiquitylation| Overexpression| Immunogenicity| Hypomethylated| Renoprotection| Pancreascancer| 
Type 58 (68): Homo sapiens forkhead box D1 (FOXD1), mRNA.| NF1 and MET; double hit on RAS pathway| HDAC4 DHFR and Thymidylate synthase| MED12 knockdown in NB7 and SK-N-SH cells| MGCD0103, Methylgene (Montreal, QC, Canada)| ERK activation is frequent in GEP-NENs| HEK293T/stable PLZF overexpression (pCEP4)| Transition from BFU-E to CFU-E stage| Genome Data Analysis Centers (GDACs)| association with FEV1 and FEV1/FVC| 
Type 59 (3): Reverse: 5'-cccaagcttGGGGATTGGGATAGGACGAG-3'| POPE/DOPC/DOPS/DOPI/cholesterol/Rhod-PE| N-Myristoyl-RKRQRAMRRRVHQING156-171| 
Type 60 (211): Leukocyte recruitment via P-selectins| Cultured T-lymphocytes and macrophages| PM blebbing by actomyosin contraction| Antigen processing and presentation| Poor prognosis Metastasis development| H3 hyper-phosphorylation & acetylation| Cholesterol/fatty acid biosynthesis| Produces changes in Golgi polarization| Erlotinib or gefitinib monotherapy| Central nervous system myelination| 
Type 61 (1373): 20.10%| 0.045*| 0.046*| 0.061*| 0.066*| 0.018*| 0.019*| 100.7%| 0.034%| 0.036%| 
Type 62 (99): BEL7402/ADM+CsA| TAF1B/mKIAA1093| MDA-MB-157+siTBX2| pERK1/2/TERK1/2| AS-KTC021-HER2TK| CD95-CD45RO-CD8+| H446AR-shKCNJ2-2| U266/pcDNA3-AGO2| PP1PP2B?PP1+PP2B| 1-G0CLBUI04IPTV3| 
Type 63 (8): -0.38±0.74 -0.38±0.78 -0.23±0.74 -0.21±0.78| PFS: 0.95 (0.78–1.14) OS: 0.93 (0.77–1.13)| PFS: 0.99 (0.73–1.36) OS: 1.02 (0.75–1.39)| -0.40±0.76 -0.42±0.83 -0.21±0.77 -0.21±0.86| -0.35±0.72 -0.34±0.73 -0.24±0.70 -0.21±0.69| PFS: 1.29 (1.04–1.62) OS: 1.24 (0.98–1.57)| 3.24 (1.06–17.58) ( P =0.0001)| v1.06393; v1.13003; v1.08735; v1.04261| 
Type 64 (113): A disintegrin and metalloprotease domain 10| Myeloid ecotropic viral integration site 1| Insulin-like growth factor binding protein 1| Localized production by Nox regulated via Ca2+| Complex with complete/partial loss of ch5| Mitogen-activated protein kinase kinase 5| Mitogen-activated protein kinase kinase 3| Multidrug resistance associated protein 3| V-akt murine thymoma viral oncogene homolog 3| Localized production by Nox regulated via Src| 
Type 65 (664): Synchronous| Pravastatin| Pirfenidone| Bevacizumab| Fibronectin| Development| Progression| Accelerated| Consequence| Centromeric| 
Type 66 (221): ? Binding of RNA| Various in CNS| Mutated in TSC| EGFR wild type| KRAS wild type| GI-I0I cell line| Obese Class III| ?Hdm2 nucleus MQS| Exposure to ROS| Solid tumor, GBM| 
Type 67 (72): photolyase, 3e-13, (BAA12067.1)| W303-1A Ifh1-myc13 ptc6::nat1| NCT01758575 (recruiting)| NCT01914484 (nilotinib)| Birinapant (TL32711)21| ZR75-1, BT474 (orthotopic)| Neuronatin (Mm.233903, NM_010923)| syIs12; lin-15B(n744)| mTH ?2707/?2749 antisense| PI3 kinase (p110a/p85a)| 
Type 68 (651): 0.59 ± 0.04| 0.59 ± 0.06| 0.83 ± 0.10| 0.74?±?0.04| 0.74?±?0.05| 1.00 ± 0.43| 0.96 ± 0.01| 0.97 ± 0.01| 0.18?±?0.03| 0.18?±?0.01| 
Type 69 (478): Vitamin D3| Histone H4| Annexin A5| Annexin A2| 1?g/mL oil| Class 3b| clone D4| clone E5| Cyclin T1| Cyclin D1| 
Type 70 (22): Rat: AGTCCATGCC ATCACTGCCA| ACAGAGGAATCCG CTGCATTC| GLYCOGEN SYNTHASE 1 (MUSCLE)| GPYLGPPHSR SSS LPDILGQPEP| CTGGTAATCTGAC ACAATGTCCT| TGTTCATCTGCAAA ATGGAAT| 63) REACTOME P2Y RECEPTORS| L1CAM INTERACTIONS (REACTOME)| GTGTCGAGTGGG metCGGAAGAA| ALCOHOL METABOLIC PROCESS| 
Type 71 (978): 25 (27.5%)| 48 (68.6%)| 77 (62.1%)| 51 (15.1%)| 21 (33.3%)| 23 (23.7%)| 87 (33.1%)| 95 (57.5%)| 12 (52.2%)| 54 (67.5%)| 
Type 72 (19): 5' - CGCTGGACCTGTGTGAACTGATGGGCCAGATC - 3'| 5' AACTCGAGGGTTTAAACTCAATGGTGATGGTG 3'| 5?-CTTGCCTACG CCACCAGCTC CAGCTCCAAC TACC-3?| 5?-GGTAGTTGGA GCTGGAGCTG GTGGCGTAGG CAAG-3?| Rev: 5' TCCAGGCCCGTTTCGTTCACCTCGATACG 3'| OXIDATIVE STRESS REGULATING PROTEINS| 3 ' - GAACTAAAGCGCCGC CACCAGGACGAAGAC-5 '| FAM-AGC TGG GCG GTG TAC GAA GTC G-TAMRA| PCGEM1 CUDR uc.73A(P) SPRY4-IT1 PANDA LUST PINC| [BCL2_DOWNREGULATES] ? [CYCS_INDUCES RELEASE OF]| 
Type 73 (10): 6FAM-ACCACCACCCAACACACAATAACAAACACA-TAMR| ACTGAACCTGACCGTACATACATGGACATCTTCTGCAC| CGTCTGTTGTGGCCAAAGCAGCAGGTTTTCTTCCACGAC| AACCAACGATTTAAAAGCTACAGTTTCTGTACTTTATTG| VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION| CAGCAGTATCGACTGGATAAAGTCAGTGCAAATGT| CCCTCGAGTTACGTCGGGGTGCCCACCAGTCCCGC| 5?-CCTTTGGGAGAGCGGCCAAAGCCCTATTCACCTCG-3?| AATAGAATTCGATATGCTTATAGAAATAGTTGTG| CGAGCTCAAGCTTCGAATTCTGATGTTTCGTAAAGCAACCAGG| 
Type 74 (27): magnesium-dependentphosphatase-1| 5’-ttgttctcctacacacatagatagggtaa-3’| 5?-aaactcgagttatcgggtcatgggtgcca-3?| Pemetrexed+carboplatin+vandetanib| Cetuximab/Capecitabine/Oxaliplatin| Cephalosporin-mustard-carbamate| N-acetylglucosamine-6-sulfatase| 5'-caactgggacgacatggagaagatctggca-3'| 5'-gaggatcttcatgaggtagtctgtcaggtc-3'| Monocyte/macrophage-activation| 
Type 75 (54): Survival/neuroprotection| Cell growth/differentiation| tgggatcataggaatgagacctg| tgccagagtctcgttcgttatcg| Glioblastoma-multiforme| tactcctctagtcctatcacctcg| Renin-angiotensin_system| cccuucaguccaaucggcgggc| gatgaaacccagacacatagca| ucccugagacccuaacuuguga| 
Type 76 (84): [ 36 , 52 , 90 – 92 ]| [ 14 - 16 , 24 , 34 ]| [ 14 , 106 , 145 ]| [ 149 , 190 , 191 ]| [ 32 , 34 , 39 , 40 ]| [ 52 , 67 , 70 , 71 ]| [ 30 , 31 , 49 , 58 ]| [ 51 , 68 , 80 , 81 ]| [ 34 , 123 , 124 ]| [ 21 , 151 , 159 ]| 
Type 77 (942): 2.46 × 103| 1.79?×?104| 2.74 × 105| 6.19 × 104| 3.59 × 104| 6.49?×?104| 54.04 ± 1.6| 488.1 ± 0.3| 244.2 ± 0.4| 322.8 ± 0.3| 
Type 78 (277): 5.91 (2.08–16.75)| 1.88 (0.28–12.59)| 6.45 (1.21–34.40)| 7.22 (0.91–57.45)| 16.50 (6.82–39.88)| 12.82 (5.08–32.37)| 69 (19.8-118.6)| 4.9 (1.27-18.85)| 1.731 (1.02-2.94)| 20.39 (11.9–34.9)| 
Type 79 (1827): BBC3| DHX9| XBP1| MCF7| BCL2| FPR2| MDH2| BDL5| DKK1| MED6| 
Type 80 (391): COP-I ?1| N6L: 10 ?M| N6L: 20 ?M| HIF-1 ?| XPR-1 b| c-KIT 3| CD8+ SP| FGFR 3c| TIG3 Rv| PTC# 46| 
Type 81 (211): Zinc finger E-box binding homeobox 2| T-cell acute lymphocytic leukemia 1| PolyA binding protein, cytoplasmic 1 b| Kdm2b lysine (K)-specific demethylase 2B| Opioid growth factor receptor-like 1| Gemcitibine, Erlotinib vs. placebo [ 15 ]| Increased levels of ganglioside GD2| Cysteine catalysis dependent on IP6| Tumor protein p53-inducible protein 3| Tissue factor pathway inhibitor-2 ?| 
Type 82 (233): GTTGAGGGCCAGACCCAGT| CTGACTCCTTCCTCACCCT| GATCCCCCTGCATTTCAGG| ATGATGTCCTTGGATGGAC| ATGGGACTTTGAGAAGAGG| GAUACAAGCUUGGCUGCUA| GACAUCUUCUGGUCAGAGA| GGUCGUGUCUGUCAAGUGC| GGGCCCCTACCTCCCTACA| AGCATCAGGCAACTCAAGC| 
Type 83 (331): Druz et al. (2013)| Yuan et al. (2014)| Bock et al. (2013)| (Tian et al., 2012)| Sicca et al. (2011)| Galio et al. (2012)| Rocha et al. (2012)| Smith et al. (1997)| Olsen et al (1992)| Frank et al (1997)| 
Type 84 (181): ?6.98±0.13 ( n =8)| ?6.65±0.16 ( n =10)| ?6.69±0.12 ( n =10)| 50 (18/36) rs = 0.68| 705 ± 146 †† (7)| 7.26±0.27 (n?=?5)| 7.55±0.15 (n?=?9)| 7.13±0.24 (n?=?5)| 7.46±0.14 (n?=?5)| 81.08 ± 0.18 ( n = 7)*| 
Type 85 (127): GGCCAAAAATTTAATCAGTGGA| ATCCCAGGTATTGGTAGGACTG| TGTTGCCATGGAGATAGCATCT| ATGCCGAGGGTGAGCCTGTATG| GACTGTGAACTGCCCATCGTTT| TAACCACCACCCAACACACAAT| CTTTGGTATCGTGGAAGGACTC| TCAGAGTCAGATGCAGGATACA| AGTGCACCTGGTACACCAAAAA| ATCTCCCACCCCTTCTTCAATG| 
Type 86 (73): ?pGEX-6P-3 Gpb1 (BamHI and NotI)| Zhou et al, “OPTIMAL” 39 (Phase III)| Occasional in AML MDS 7% MPN 3–13%| HER3/Rluc8 + Grb2/Venus + EGFR| pros- GAL4; UAS- mSox2 EnRep| ARR 2PB - hepsin / ARR 2PB-myc| pACT2-GAL4-HA-IQG1 gene fusion| TMPRSS2-ERG negative ( n =23)| Examples: Xist, APOA1-AS, GLl1AS.| AJCC (stage III/IV vs. stage I/II)| 
Type 87 (133): ?Muscle contraction (BP00173)| Overnight at 4°C 1:50 dilution| tubulin, alpha 3A (Tuba3a)| Rajab and Handam 2002, Jordan(64)| mRNA catabolic process (0.00769)| Cell proliferation (HT-29)| 85 (localised disease) 18 (HRPCa)| Laminar flow(12 dyne/cm2)| Ca2+ channel (?2? subunit)| Unc-5 homolog C (C. elegans)| 
Type 88 (3): V10 · [MAPK-P]/(K10 + [MAPK-P])| Y [T/A/S][K/R/Q/N][M/I/V/R]| GAA[A/T][C/T]G[C/T][C/g/t][A/T][C/T/g]| 
Type 89 (89): APOE, CR1, INPP5D, PTK2Ba| AKT1, AKT2, PIK3CA, PTEN| ACTB, ACTN4, RAB3B, YES1| XRCC6, HNRNPA2B1, XRCC5| OGG1, XRCC1, APE1, PARP1| PLCZ1, FOS, JUN, PLCL2| CFDP1, DGKG, GAS1, PAX6| IL1B, HSPA5, PRNP, IL1A| BST2, PDCD4, TGFBR3, VEZF1| LOC, DGCR6, PRODH, DGCR5| 
Type 90 (2969): 124.1| 999.7| 125.8| 95.13| 83.33| 95.39| 95.58| 95.59| 365.3| 95.67| 
Type 91 (231): IGF-1 Signaling| HIF-1 Inhibitors| CTLA-4 receptor| STAT3 inhibitor| TGF-?1 receptor| BRCA 1/2 mutation| JAK1/2 inhibitor| E/ER Repressed| Pasireotide (SOM230)| FLT3+AML untreated| 
Type 92 (336): Time of recurrence-free survival| Genes overexpressed in leukemia| Involved in chromosome cohesion| Increased likelihood of relapse| Retinoic acid metabolic process| Glutamate molecules per vesicle| Toll receptor signaling pathway| T-cells activation and motility| Crossover for placebo patients| ?Promotes endothelial function| 
Type 93 (1830): 0–1174.2| ?2.08471| ?0.25464| 0–1428.9| -0.66472| 165±30.5| 114±0.66| 114±0.23| 115±0.22| 3.46E-25| 
Type 94 (1349): 2C| 2D| 3B| 3K| 4A| 4N| 4X| 5B| 5R| 6X| 
Type 95 (45): 5'-CACAAAACTAAACATATCTAAACCCT-3'| 5?-AUAUGUAGAGGCUGUGAUCAUGAGG-3?| 5?-GGCTCTTATCACGTTCTTCAAGTTT-3?| 5'-GGCAGGAGGCAGACGUUGGCAGUGGCA-3'| 5?-AGTCGCCAAGCGCAAGAGATCAGCGCC-3?| 5?-TGGGGAGGGTGGGGAGGGTGGGGAAGG| (FAM)-GGCGCCTGGTCACCAGGGCTGCTTT| RNTQPVLNLHPAAAPT(ph)NDAGLAVVDGK| AGAGAACGTGACACGTTCGGAGAATT-3?| 5?-TGTGCCCATCTACGAGGGGTATGC-3?| 
Type 96 (1021): [ 168 ]| [ 141 ]| [ 167 ]| [ 144 ]| [ 143 ]| [ 169 ]| [ 146 ]| [ 122 ]| [ 121 ]| [ 147 ]| 
Type 97 (98): GDC-0941 (PI3K p110?)| STK15/BTAK (20q13)| BHP18-21v (TTF1)| TF-1, KU812, MEG01| M2. PIK3CA -H1047R| cTNF-RI aa 206–426| D12Z1x8–12, MDM2>20| MYD88 L265P (91%)| XY244 ( CAP1 ?P2)| EGFR mut T790M, G719A| 
Type 98 (261): PaCO2 (mmHg)| A R-neur| Others (IC50)| Lm -dd-TV| Ca2+ -ATPase| NS/S ratio| KRAS [utr3]| Iota (1GIQ)| BH3 Domain| Stage T1–T3| 
Type 99 (6): (10.4%/20%/22.6%/47.0%)| –0.78 × 10–4–1.4 × 10–4| –0.45 × 10–4–1.8 × 10–4| 30–50/12–32/15/2.5/0–40/0.25| Chr:17?8023908:8027410:-1| ?18q21.2<48.99–51.05>[0.55]| 
Starting to cluster headers....
500 tables processed...
1000 tables processed...
1500 tables processed...
2000 tables processed...
2500 tables processed...
3000 tables processed...
3500 tables processed...
4000 tables processed...
4500 tables processed...
5000 tables processed...
5500 tables processed...
6000 tables processed...
6500 tables processed...
7000 tables processed...
7500 tables processed...
8000 tables processed...
8500 tables processed...
9000 tables processed...
9500 tables processed...
10000 tables processed...
10500 tables processed...
11000 tables processed...
11500 tables processed...
12000 tables processed...
12500 tables processed...
13000 tables processed...
13500 tables processed...
14000 tables processed...
14500 tables processed...
15000 tables processed...
5 iterations done
10 iterations done
15 iterations done
20 iterations done
25 iterations done
30 iterations done
35 iterations done
40 iterations done
45 iterations done
50 iterations done
55 iterations done
60 iterations done
65 iterations done
70 iterations done
75 iterations done
80 iterations done
85 iterations done
90 iterations done
95 iterations done
100 iterations done
Type 0 (5055): No. of genes in pathway| BAC number| Chrom.| c-Met| Pediatric| Charge| Peps| Chimpanzee| Number§| Eye Score| 
Type 1 (864):  | Normal| Response| +| Expression| All patients| Experiment| (A)| Controls| Proliferation| 
Type 2 (1183): RR (%)| CM| Tissue weight (mg)| Rate ratio| SD (%)| Microarray Fold Change| TTP months| MCF-10A| I. vs IC.| Total Expression (mg / l)| 
Type 3 (473): Patients characteristics| Adverse event| Clinicopathological Features| Clinicopathological variables a| Host| Characteristic at initial diagnosis| Functional Group| Orientation| Ethnicity| Clinicopathological factors (N = 56)| 
Type 4 (40): 31| Complexes| Relevant Gene Ontology Biological or Molecular Designations| Functions of non-septins| Kind of approach| Biological consequence| Viral Agents| Combination therapy| Plant biological pathway| Replication participants| 
Type 5 (461): Published biochemical IC50 (nM)| Biennial gFOBT| YFC| IE network| 10.5 hpf| Validation Set (FRA)| K M (? m )| ISEL| Allele frequency c| K d,AZ-AZI (µM)| 
Type 6 (320): Event frequency, (%)| Mc(Hs)| 1O2G(%)| Milk fat percentage1 (×100)| anti-P25 positive (%)| CLP| Percent of S cells (SD) *| rs17849071G/T, n/N (%)| C. sinensis sequences (%) a| Obese ( n = 9)| 
Type 7 (49): KOG Information| BOND2| Total patients| Etiology| GO term| B. subtilis Obg as template| Functional annotation| Data Type| term| Mechanism| 
Type 8 (661): Ratio H/L Normalized| Proposed binding site residue| Ad5| myrArf1| Number of cells screened per selection| Plasma or Sera| Day 8 Notch OFF versus Day 5| CI(ED50)| Fold log(AD/N)| Class II| 
Type 9 (63): Effects of the miR-34/chemo combination| Clinical applicability of PARP inhibition| Duration of post-transplantation experiments| Putative Biomarkers| Tumor cell line| miR-Mask| Incubation time and temperature| Usual dose (daily unless mentioned)| Pros| Estradiol Regulated Genes| 
Type 10 (259): 10-CV| F344_Sal| Macrophages positive (%)| Probe set id| dbSNP 1| Number of aberrant crypt| IR6+FA| NgBR Score| %S| MTT (OD value)| 
Type 11 (148): Pham et al. [ 15 ]| Role/Function| HOPX expression| Expressing tumor type| Gene prediction| GO categories| Measurements| Mushroom species| Mutations induced in E.coli only (%)| Attributes| 
Type 12 (156): GenBank #| Genbank Accession Numbers| GB a accession #| Affymetrix gene| Gene (Location)| AccessionNo.| Clone accession no.| Name/ID| Search key| Assay code| 
Type 13 (232): 1990–2008| Probe IDs| D 0| Vehicle ( in vivo )| ABW ( n  = 12)| LH (ng/ml) N.S.| 1w| FPAs| 6w| DMI| 
Type 14 (51): Reaction class| Transfection reagent| Substrates/targets| Tumor State| Model name| Macro-parameter definition| Viral Proteins| Known AS Event 2| Significant TFBS present in all promoters of a given cluster 1| Significant TFBS present in all promoters of a given cluster 2| 
Type 15 (490): Gene Name a| Region on protein| Deletion pool source 3| Candidate Cancer Related Genes| End-Point| Gene name b| Pathway(s)| Biopsy origin| Differentiating group| Cluster 4| 
Type 16 (347): ALT (U/L)| Phase III 6 Ipi and DTIC (Ipi at 10 mg/kg) 250| CRF| % G2/M| Diet-induced obese rats (DIO)| Reference ranges| Number of patients (n=100)| Case 13| Mean fluorescence intensity| Risk-matched Control group ( n = 33)| 
Type 17 (1699): Ratio (C3/C5)| # amino acids| OR $| Whole Cell| DA mimic| Fold changeearth| Control vs. acid| sequence coverage (%)| MW(kDa)| Survival Rate| 
Type 18 (540): E2197 NNN vs PXN| Adjusted P-value d| P value ( vs. benign meningioma)| significant p-value <0.05| Average MediaSpot %| Freq CIMP?| AverageMY Spot %| Raw p-value| Control D5W| Number of samples of heavy smokers with mutations (Mutation frequency in 17 samples)| 
Type 19 (198): Clinical study| Trial stage| Acute GVHD| Current use| Inhibitor (company) commercial name| Mutation/ polymorphism| NS d| Clinical trails| Sizes (kDa, or disachharide)| RAR?2 region| 
Type 20 (177): Model| Description| Regimen| Type of Cancer| Name| Names| Gene set| (B)| Purpose| Pathway| 
Type 21 (75): Structural element| Nanosystem| Mating yeast strain| Dietary Factors| Annotation c| Experimental Conditions| 1st Key node| EGFR peptide sequence| Cancer model| Synonyms, mouse| 
Type 22 (48): Primer sequence (5?>3?)| Forward Primer (5' to 3')| Sense (5? to 3?)| Oligonucleotide sequence (5'-3')| Forward Sequence| Primer sequence 5?–3?| Reverse Primer (5' to 3')| Forward primers (5?-3?)| Reverse 3?-5?| Reverse primer 5 ? ?>?3 ?| 
Type 23 (82): Potential genes| Gene_id| CKA| KA| Methylated sugars| Database entry| Best Hits with miRNAs in miRBase| Unigene_ID| Nanomaterials| hsa-miR| 
Type 24 (1719): Patient| No. of patients| Fungal Strain| Aga| SD (g/kg diet)| pEGFR| ESCC (n=27)| EGFR| Tiam2 Native I| KKAy-Vehicle| 
Type 25 (417): GNAQ mutation| Localization of primary| 17q-gain| 11q-del| Other tissues affected| FXFP motif| C. elegans homolog| Site(s) with the consensus PX(S/T)P sequence| Human gene| gene:| 
Type 26 (70): Name of the encoded protein| Author (reference)| Metastasis sites| Author and reference number| Fraction number| Known or proposed functions| Injection/ Lens treatment| Source of Organisms| TBK1| Tannin| 
Type 27 (287): Reference number| [35S]GTP?•Rac1 (cpm) (% of control)| Results of patient studies| ?log ( P value)| Apc| Iron-loaded rats| CKD| Lon protein expression| Heart rate (beats/min)| Number of GFPhi leukocytes d| 
Type 28 (22): Drug (clinical trial sponsor)| Num. of novel genes & stages where these are identified| Treatment (line)| Notes/Company| Epigenetic changes in CRC| Major genetic alterations| reservoir solution| Transfections| Inclusion criteria| Multiple target| 
Type 29 (30): Genes of cytochrome subunits| targets and subjects| MRI| Primary Endpoint(s)| Mast Cell Type/Origin| Animal protein [g/y]| Data sources and data types| Pollen tubes and root hairs| Knockout mouse phenotypes| Effect of ZA| 
Type 30 (467): Clone #| Adenylyl cyclase activity (pmol of cAMP/mg/min) a| MS Mass| Extended 24 h| Time ?=?12h| SHANK3| rs11599672 (cases/controls)| ?Ct in qRT-PCR ( Mean ±SD)| Significance (hypergeometric distribution)| GT counts controls| 
Type 31 (140): PPI subnetwork| Interventional scenario| Therapeutic Agent| TF Matrices| 18| Immunotherapy group| Seed sequence| Uniprot Accession| Traits 2| Adapter molecules| 
Type 32 (107): Reverse Primer Sequence (5?-3?) [RP]| Primer sequences (5? to 3?)| Forward primer (5'...3')| Sequence 3| 3? GSP Sequence| phosphopeptide| Forward primers (5?–3?)| Sequences (5?3?)| Primer Reverse (5'-->3')| Phosphorylated peptide 1| 
Type 33 (223): Permutation R 2(2)| 95% Confidence Interval of Hazard ratio| Ad-36 positive| WT-CTRL (n?=?6)| Phase-III 5 Ipi monotherapy (3 mg/kg) 131| Particle Associated HIV (248)| k obs (min-1)a| Phospho site a| Succinate (n?=?8)| TNF +LOS| 
Type 34 (36): Isoform targeted| DNA Analyzed| Radiosensitization| Cell-line| CLO segment length| Tipifarnib a dose-schedule| Immune measures| KRAS genotype| First name STUDY| PDGF| 
Type 35 (201): Selected by EGFR positive| Angiogenesis| Mets in animial| Organ/tissue/cell type| Compartment| 2. Extent of conformational change at the substrate site| Cancers| Sequencing strategy| Cancer Examined| Salivary gland| 
Type 36 (71): Domains a| Clusters a| Matrix protein coating concentration| Tumors/Injections Nude Mice (?T cells)| Cluster (genes)| Author [reference]| Docking Score (kcal/mol)| Prognostic indices/covariate model ( n )| Dilution and incubation time| Author, Reference, Year| 
Type 37 (418): Fold Change: Differentiating group vs. other groups:| Primary Resistance, Median (Range)| Active GSK-3? Positive (%)| p (%)| CRC n = 30 (%)| Fold change (log 2 mean)| Control (n=8)| Loss of Stent| C40| Frequency (Percentage)| 
Type 38 (216): Direct TPG| Lymphoma**| RTKs| MODULATED BY 5-AZA-CdR| Pearson's correlation| Rodent| KRAS Mutationc| Target antigen| Pfam Domain| IgG| 
Type 39 (77): Air| Reverse PDS (ATCCCT)| WCC(x109/L)| Adjusted OR(95% CI) a| Taqman Assay ID| Assay reference| Fitted parameter q1 [ml O2/(105 cells min)]| Control (MAF)| Conserved gene in A. thaliana (E-scroe)| Nucleotide change a| 
Type 40 (119): SOD (U/mg protein)| Control ( n = 32)| Total number of fragments| Mgat5?/?| Promoter sequence| Apoptotic cells (% of total)| BJ + AOM 4.1? ? L/g + 10?mg/kg| Plasma triglycerides (mg/dl)| G1%| DH rat| 
Type 41 (80): Nucleotide Alteration| Motif (BR)| 5'| Function and tag sequences| Tag sequences| Profibrotic Signalling Pathways| MDR-related ABC transporters involved| FDR < 0.05| SEQUENCE| predicted to connect to gene(s)| 
Type 42 (37): EPOR expression as PF (method)| Overlapping entities| Prostaglandin| BRCA| Diabetes/renal| SYNDROME| Targets: notes| Nearby expressed coding and non-coding RNAs| Mode of actions/targets| MS/MS fragment| 
Type 43 (19): cell type/intervention 1| cell type/intervention 2| Analyzed samples| Gene Family| Perturbation| Modeling Approach &Methodology| Used cells| Centre Name| Gene Title (Target Description/Symbol)| Study results| 
Type 44 (22): Homologous Human Genomic Segment (Human Chromosome Number: From Base Pairs to Base Pairs)| MMP-9 (ng/ml)| cv-SMSE (0.05, 0.5,0.95 quantile)| Target scan's Context percentile/Mami score(in decimals)/miTG score ( in italics )| Trial Reference Number| Papillary carcinoma ( n =31)| Position [UMD 3.1]| OR, 95% CI a| Fold change (6, 24, 72, 120 h)| LVI, n (%)| 
Type 45 (63): XRCC1-| ERCC2-| Testing stage a| Strain or plasmid| Tool name| Dose (range)| Green Label| Treatment Cell Line| pMyr| Structure match| 
Type 46 (144): Cell of origin| Function (Species)| Expression levels in GC tissues| Dir| miR-34| Macrolide| Modification of Smad7| Relevant histological subtypes| Deregulation| Effector T cell| 
Type 47 (96): Amino-acid substitution| Given| List of primers| HDAC Isoforms| Distribution patternb| Candidate binding factor for TRE| Character| Media VEGF Protein| Mismatch ¥| Sequenom's Assay Name| 
Type 48 (46): mechanism| Inducer| Phyllanthus ?species| miRNA target and its role in cancer| Kinetic law| Sex of patients| Recipient Mice*| Pro-angiogenic effect| E/ER sensitivity| VDR Phenotype| 
Type 49 (55): Functions in Membrane Trafficking| Circumstances| Ghrelin| GEP| Cell line derived from| The anti-HCC effects| T3SS Description| common SE| Operation| Recommendations| 
Type 50 (69): Clinical associations| Parameters/Rat groups| Translocation effect| WHO-EORTC| Hereditary breast and ovarian cancer syndrome| Effect in PCA| Sampling size| Activity/TCR-dependent signaling pathway| Outcome Measures| Protein interaction| 
Type 51 (37): Tumor + COX-2 siRNA State| Target name| Cause of over and underexpression| Sequence (5??3?)a or description (Restriction sites are underlined)| Primary antibody incubation| Label/time point| Heavy metals| Second antibody| Protein Identification| Processes(p-value)| 
Type 52 (83): Net displacement (µm)±SD| T3| ORhet(95%CI) b| Rectal prolapse (n=6)| 4–10| Sequenced bases on target| Specificity (95% CI)| Univariate analysis HR (95% CI)| Hazard Ratio (95% confidence interval)| Probe ID (Agilent 44 k)| 
Type 53 (48): Method for measuring ROS production| PATIENTS pre-treatment| Observation in PCOS| Expression level and modification of Schwann cell proteins| Different categories| Screening Modes| REACTOME Pathways| Cell Types| Effect on PML| GOTerm, DAVID-level3| 
Type 54 (44): Source of PCSCs| Pfam Domain, Remarks| Form of Silk| Characteristicsa| Clinical association (References)| Gene name (some shortened to fit)| Phenotype and latency (non-infected versus infected with M-MuLV)| Cell line (Transfectant or treatment)| Cell Stimulus| Purpose of analysis| 
Type 55 (104): Probeset| OSt| OSm| Ground Control| Cell cycle distribution (% ± SE)| Geom mean of intensities in chordoma| Voltage dependence of inactivation| the phosphorylation of Akt| 95% CI| SNP| 
Type 56 (270): Polyphen g| Wilcoxon Test| Fold change (MA:MB) *| <CC>| AKT2| NF1 patients| 3 weeks| Interactions| Spot number| H3K27me3| 
Type 57 (68): Identification method| Activated Pathways| Associated cancer types| Human tumors| Ingenuity canonical pathways| Regulated pathway| Protein type| Clinical trials| Product name| Associated Tumors| 
Type 58 (53): phenotype| Downstream consequences| Authors, year of publication| Variables *| Residue| Trial type| Author, year| Method: Enzymatic| Experimental localization *| Cellular function| 
Type 59 (64): Aim| Family PDB chain| MGUS| Tumor selectivity| Targeting mechanism| miR-21 expression in human tissues/cells| Description b (SGD)| Type of Peptide Evidence| Genes overexpressed in the tumour:| Possible mechanisms of anti-HCC| 
Type 60 (293): TO30.01| Endo-cardium| Invasion front| Mean severity| NaCl followed by oxaliplatin| Oxaliplatin followed by NaCl| Fold Change c| LBFC| CHISQ| FC microarray| 
Type 61 (468): Effect of somatic mutation| Swiss-Prot hit| Country/ethnic group| Model type| Tumor localization| Country Loa Acquired| Chromatin State at TSS| Representative homologous protein(s)| Arf| Primary location| 
Type 62 (95): Disease B| information| Effects on HBV transcription and replication| Associated disease| Type of injury| Descriptive title| Type of particles| Immune effector response| Recommended dose modification| Type of alterations| 
Type 63 (12): genes presumably up-regulated proteins| Genes identified| Gene_Symbol| Target genes in DEGs| Transcriptome study 13| NGF induced molecules| Gene/mutation*| DDX18 -associating proteins| COAD| Molecular Pathways 1| 
Type 64 (16): Patient numbers (treated/control)| webpage| Signaling cascade/effect| Mature miR sequence| Predicted Mature miRNA *| Ab type| Right Primer| Oligonucleotide Primers| Source ofcontrols| Sequence (5?- 3?)| 
Type 65 (34): HT| peptide| Hub genes| supported by data?| CBM location| Growth factors and cytokines| Markers used| Consensus binding motif| Kb binding peptides| entry name| 
Type 66 (61): Pathways and gene sets enriched by up-regulated genes| Discovery cohort size| Correlation with overall survival and outcome| DLT| Annotations| Functional annotation by DAVID| Oncogene classification according to their functions| Type of cell death| Classical Analysis by GeneSifter| Differences compared to sporadic tumours| 
Type 67 (605): Name| Pathway| Treatment| Tumor type| Model| Cell type| Classification| Description| Function| Disease| 
Type 68 (68): Table Name (Size)| Other Aliases| G4| gene(s)| Approach using HA-binding peptide| Genes Identified in GO Terms| Responses to cytokines| Trials [Reference]| HHV-8 genes| Alteration type| 
Type 69 (41): Microarrays plataform| Template structure (PDB accession code) #| Molecular mechanisms of action| Genetic aberration| MSigDB annotation (Source)| Example cases of Mutation disambiguation dictionary records and patterns| Gene symbol//gene title (ref #) – functional categories| Drug manufacturer| Parameter description| Blood/bone marrow| 
Type 70 (56): BMP3b Meth| TFA| IC50| Concurrent BMP3b and BMP6 Meth| MXR| VEGF-D/VEGFR2| Initial TM Dimer Structure| Pt| Kras gene codon 12None/Either/Bothp-value| RASSF1A geneNone/Either/Bothp-value| 
Type 71 (239): p -value of overlap| Chromosome location| Cytoband| End| Molecular weight| 6 h| Mutation rate| T4| GenBank ID| Chromosome Location| 
Type 72 (35): MMTV-Wnt1/p53 +/-| Standard conditions| Disease and number*| treatments| Agents (dosage/day)| GI>50 (?M ± SD)| Phosphate-limited medium| (1) Animal models of colorectal carcinogenesis| Coadministered drug| Other names for the drug| 
Type 73 (20): GENOTYPE| Category name (Accession)| Case 14| Genotyped samples| Case 3| Insert Gene| Name of oligonucleotide| SNP a| MEFs’ Genotype| Endothelial Cell Surface Receptors/Activator| 
Type 74 (37): Pretreatment HGF level (cutoff value: median)| Pretreatment EREG level (cutoff value: median)| Event-Free Survival| Overall death| Ouabain| Weight (g)| OSCC-specific death| Hazard ratio (95% confidence interval)| Pretreatment HGF level| OR 95% CI| 
Type 75 (322): Biological intervention| Effect of neuropeptide treatment on LH release in vivo| Role of autophagy| Rat parathyroid| Newly Dx vs Progression| Effect on IRES activity| Activatory| Disease Group| Cytogenetic risk group| Consequence of alteration| 
Type 76 (51): Example(s)| Participants or cells/treatment| Gene Description:| tissue| Tumor latency| Official gene symbol| Tumors (estimated penetrance)| Rosuvastatin dosage regimen| Fungal species| Proposed Functional Effect| 
Type 77 (26): Direction and strength of correlation (R value range) c| H2052| C51S| Holding time at 17 ° C| C80S| H-RasV12C40| Group EAM (n=6)| Upper versus lower lobe| V max (pmol/min per mg)| Expression of TET2| 
Type 78 (114): KEGG Pathway Name| Biological Function| Functional Class| Phenotype investigated| Clinical parameter| Lesion| Genetic abnormality| Gene function| EASE Term| GO biological process| 
Type 79 (105): Real-time experiment| HUVEC| Fold change ( P value)| BMP6 Meth| Heat-induced unfolding| 60 min| p -Value| Luteolin| Hazard Ratio(95% CI)| MCD-V (n=7)| 
Type 80 (43): FACS, cerebral astrocytes*| Growth Traits b| FACS or otherwise identified cerebral neurons*+| Study and year| First AutorYear [Reference]| Author, reference, year| First author (reference)| REFs| Published/author| Study ID| 
Type 81 (35): Reverse primer sequence (5'?3')| 5?-sequence-3?| Reverse Primer 5?-3?| NCBI Accession number| Reverse (antisense) primer| Results: neuroimmune| Antisense primer sequence (5?–3?)| Reverse 5??3?| Human GenBank accession number Sequence 5?–3?| ???????? Reverse primers| 
Type 82 (26): STAGE/PATIENTS| Rev Primer Seq| Address| Fwd Primer Seq| Main BioPAX Classes Used| Oxysterols| Result of GO TERMFINDER & DAVID level 3| Type of attenuator| Myeloma patients| Hormonal profile| 
Type 83 (144): References| Reference| Fisetin| GDC-0941/PD0325901| Refs| Flux (% Control)| REF| Galangin| Ref| REF.| 
Type 84 (23): Ras Proteins| Native peptide sequence| Gene Name/ID| TFBM| Cell Phenotype| Sequence(5? to 3?)| Primers used in real-time PCR| ArrayExpress or GEO accession| Bm_CDS| EST No.| 
Type 85 (408): Duration| Binding partner| Mouse Homology| Follow-up| Number of changes a| Country| Fusion| Confidence level| Tumour type(s) screened| Quercetin (pure)| 
Type 86 (21): Sequence of forward and reverse primers| Incident of Genetic/Epigenetic Cell Cycle Alterations| Cohort size| Phase of experimentation| Experiment source scenario| Study participants| GO term (bp)| Nuclear a| Percentage (%) of cases found| Observations and Inferences| 
Type 87 (12): 76| KD Expression| IC 50 (?g/ml) ± SEM| SD Expression| COPD ( n = 48)| 76.2| 76.4| Conidial Volume (?m3)| AUC (days)| AX2| 
Type 88 (3): Sequence (5? –3?)| Sequence (5?–3? for DNA or N to C for PNA)| 5?-3? nucleotide sequence| 
Type 89 (145): Vector| Fusion protein| Kinase(s)| Sample name| Protein target| Official symbol a| TKR| Assay method| Cell lines 2 )| Vertebrates| 
Type 90 (158): Set7| Ensembl ID| CNE-2| PVal 116?114| Protein (% of control) a, b| 4 d| Adj. pvalue| Core Haplotype Frequencies| 29| LZR| 
Type 91 (424): Gene| Molecule| Genetic marker| Target protein| Diagnosis| Target| Human homolog| Proposed substrate| Gene names| Gene symbol| 
Type 92 (8): Diagnosis (n)| Implementation| Developmental stages investigated| Extracellular and Ligands| HUGO gene symbol| Subnetwork| Genes (Number of Mutations)| Binding Site on ROCK| 
Type 93 (291): Day 5| HWE| v4| RRM1 p| Folds (Al vs control)| Basal situation| Publication bias| Predicted values for an additive effect| FDR:| DC| 
Type 94 (79): Translocations| OS mt KRAS: control vs. EGFRI (Hazard ratio)| 8?hr reperfusion| cell diameter (?m)| Centrosome proteins| Frequency of missense mutations in breast cancer (# most frequent in breast cancer); in other tumors (# most frequent)| Frequency (FD) a and level of mRNA decrease (LD av ) b| Wt KRAS (%) Responders (%)| Location (proximal versus distal)| HRG| 
Type 95 (81): comments| CSC culture conditions| Pathogenetic Mechanism| Dosing Regimen| Subjects and approach| Working mechanism| Associate function| Clonorchis sinensis predicted proteins (50,769) similar a to those in:| Molecular testing & kits| Functional Annotation| 
Type 96 (4): GenBank accession numbers| Selected functional event| References (PudMed)| Matching alignment UniProt or EST accession number| 
Type 97 (548): Recurrence-free survival (months)| Relapse free survival analysis (Logrank P )| Repressed in log phase by Gis1 a| GBM6| Fold induction| IC50 value (nM)| Expression array (log2 ratio)| In combination with LSM| HIV vs. HIV?+?TAK| GATA-4 Expression| 
Type 98 (26): Reverse primer 5??3?| Reverse primer sequence (5????3?)| Antisense primer| Probe (5?-3?)| modified peptide(s)| Telomeric repeat| Sequences (5? ? 3?)| Sense/Antisense: Sequences| Primer Forward (5'-->3')| Primer sequence : (5?-3?)| 
Type 99 (14): Isoforms Investigated and References| Mgat5?/?ESC| Regions lost in ? five cases| UKF-NB-4 Hi vs UKF-NB-4 (rank a / P -value/genes affected b )| Human Similarity| Click Beetle Red (Pyrophorus plagiophtalamus)| Virus titer used [reference]| Cardiomyocyte diameter| Number of colonies/ 105 cells/?g plasmid DNA| ESC-Rescue| 
